New Cholesterol Pill Reduces Heart Attack Risk with Once-Daily Dose

A new experimental drug, Obicetrapib, has shown promise in reducing LDL cholesterol and lipoprotein(a) levels in a Phase 3 trial, potentially offering a convenient once-daily option to lower heart attack and stroke risk, though further research is needed to confirm its impact on actual cardiovascular events.